

TITLE:

A video protocol of a randomized controlled clinical trial - electrochemotherapy of cutaneous metastases with reduced dose bleomycin (BLESS Trial)

AUTHORS AND AFFILIATIONS:

Tolstrup MA (Marie Abildgaard Tolstrup)^{1,2}
Lonkvist CK (Camilla Kjaer Lonkvist)³
Rosted EE (Elizabeth Emilie Rosted)^{1,4}
Alrasheed T (Taiba Abdulmohsen M Alrasheed)⁵
Bastrup FA (Freya Armstrong Bastrup)¹
Mojsoska B (Biljana Mojsoska)⁶
Plesnik H (Helena Plesnik)⁷
Kosjek T (Tina Kosjek)⁷
Hölmich LR (Lisbet Rosenkrantz Hölmich)^{2,8}
Krezdron N (Nicco Krezdorn)⁵
Gehl J (Julie Gehl)^{1,2}

1: Department of Clinical Oncology and Palliative Care, Zealand University Hospital, Roskilde, Denmark

2: Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

3: Department of Oncology, Copenhagen University Hospital Herlev and Gentofte Hospital, Denmark

4: Department of Regional Health Research, University of Southern Denmark, Denmark

5: Department of Plastic Surgery and Breast Surgery, Zealand University Hospital, Roskilde, Denmark

6: Department of Science and Environment, Roskilde University, Denmark

7: Department of Environmental Sciences, Jožef Stefan Institute, Jamova 39, Ljubljana 1000, Slovenia

8: Department of Plastic Surgery, Copenhagen University Hospital Herlev and Gentofte Hospital, Denmark

Email Addresses of the Co-authors:

Tolstrup MA	maato@regionsjaelland.dk
Lonkvist CK	camilla.kjaer.loenkvist@regionh.dk
Rosted EE	eros@regionsjaelland.dk
Alrasheed T	taia@regionsjaelland.dk
Bastrup FA	freya.armstrong@hotmail.com
Mojsoska B	biljana@ruc.dk
Plesnik H	helena.plesnik@ijs.si
Kosjek T	tina.kosjek@ijs.si
Hölmich LR	lisbet.rosenkrantz.hoelmich@regionh.dk

Krezdorn N nkre@regionsjaelland.dk

* Corresponding author: Prof. Julie Gehl, Center for Experimental Drug and Gene Electrotransfer (C*EDGE). Department of Clinical Oncology and Palliative Care, Zealand University Hospital, Sygehusvej 10, 4000 Roskilde, Denmark. E-mail: kgeh@regionsjaelland.dk.

SUMMARY:

This video article presents the protocol for a double-blinded, randomized clinical trial investigating whether electrochemotherapy (ECT) with half-dose bleomycin provides non-inferior tumor control compared to the standard regimen. The protocol integrates standardized response evaluation, a description of pharmacokinetic analyses, and patient-reported outcomes to support dose optimization in clinical practice.

ABSTRACT:

Cutaneous metastases in patients with incurable cancer represent a significant problem — they often cause pain, discomfort, and emotional distress that affect everyday life. Finding treatment options that are effective but also gentle is essential. ECT offers one such possibility. Here, short high-voltage electrical pulses applied directly to the tumor briefly open the tumor cells, allowing chemotherapy to enter more effectively and kill the cancer cells. Traditionally, patients receive 15.000 IU/m² bleomycin intravenously, but emerging evidence suggests that a lower dose might work just as well while causing fewer side effects.

This video article demonstrates the protocol for an ongoing double-blinded, randomized clinical trial investigating whether ECT with half the standard bleomycin dose provides non-inferior tumor control compared to the conventional regimen in patients with cutaneous metastases. The article outlines randomization and blinding procedures, pretreatment evaluation, bleomycin preparation and administration, electrode placement, pulse delivery, and response evaluation using the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria. In addition to clinical response at three months, the protocol includes pharmacokinetic blood sampling and qualitative interviews with the patients to enable a comprehensive evaluation of treatment impact. Baseline tumor characteristics from the first 15 enrolled patients and an example on how mRECIST are applied are presented. Critical steps to ensure methodological rigor are discussed, including standardized tumor measurements, consistent electrode positioning, and predefined management of confluent or poorly demarcated tumors.

By visually outlining the procedural workflow and key methodological considerations, this article provides a reproducible framework for dose optimization in ECT and supports future implementation of reduced-dose regimens in clinical oncology practice.

INTRODUCTION:

Cutaneous metastases represent a distressing clinical manifestation of advanced malignancy, most commonly observed in patients with breast cancer, malignant melanoma, and lung cancer, although they may arise from a wide range of primary tumors¹. Between 0.7 and 9% of patients

within these diagnostic groups develops cutaneous metastases, a condition generally associated with poor prognosis and substantial disease burden¹. These patients are often heavily pretreated and clinically fragile, making therapeutic options limited. In addition to reflecting advanced disease, cutaneous metastases significantly impair quality of life, due to pain, odor, ulcerations, and psychological distress from their visible and progressive nature^{2,3}.

Local treatment modalities therefore play an important role in symptom control and local disease management. In addition to surgery and radiotherapy, ECT has emerged as an established local treatment option for cutaneous and subcutaneous metastases. ECT combines the administration of chemotherapy – most commonly bleomycin – with the delivery of short high-voltage electric pulses that transiently increase cell membrane permeability, thereby enhancing intracellular drug uptake and cytotoxicity⁴. In the broader literature, ECT is increasingly recognized as a valuable component of multidisciplinary cancer care, with European guidelines recommending it as a treatment option for cutaneous metastases of various origins^{5,6}. Given its localized nature, high response rates⁷, and quality-of-life benefits, ECT may be particularly appropriate for patients with limited treatment options and recurrent tumors.

This protocol and reduction of bleomycin is particularly relevant for patients with multiple cutaneous metastases who require effective local control but may be vulnerable to systematic toxicity due to prior treatments, comorbidities, or advanced disease status. In such patients, optimizing the balance between efficacy and safety is critical.

Questions regarding optimal drug dosing—such as whether bleomycin doses can be reduced without compromising efficacy—remain an important area of ongoing research⁸⁻¹¹, as reducing systemic exposure could further improve safety for vulnerable patients.

In this video presentation we present a randomized, double-blinded clinical trial investigating whether half dose bleomycin is noninferior to the standard dose in the treatment of cutaneous metastases using ECT. The study design is displayed in Figure 1. Moreover, we describe how the pharmacokinetics of bleomycin in tumors, normal skin and in the patients' blood will be assessed, as well as how we conduct qualitative interviews to investigate the patients' experiences of having cutaneous metastases and the treatment with ECT. The protocol seeks to include approximately 110 tumors from around 55 patients with non-curable cancer, and is described in detail by Tolstrup et al.¹². Outcomes for BLESS Trial are presented in Table S1.

[Place **Figure 1** here]

PROTOCOL:

Ethical and Regulatory Considerations

The trial has received approval from both the Danish Medicines Agency and the Regional Committee on Health Research Ethics (CTIS no. 2024-513360-25-00). It is conducted in accordance with the Declaration of Helsinki and the principles of Good Clinical Practice (GCP) and is overseen by the GCP Unit in Copenhagen.

Eligible participants are patients who would otherwise qualify for ECT, thereby ensuring that study participation does not introduce additional treatment-related risks. Written informed consent is mandatory, and all participants are covered by the Danish Patient Compensation Scheme.

The patient/patients who participate in this video will be asked to sign written informed consent through a patient release form from Zealand University Hospital.

1. Randomization and Blinding

- 1.1. Generate the allocation sequence independently of the study team before patient enrollment begins.
- 1.2. Use the web-based randomization service Sealed Envelope (Sealed Envelope Ltd., London, UK; <https://www.sealedenvelope.com>). For this trial the service was accessed in August 2024.
- 1.3. Perform block randomization with a block size of ten within each stratification group; one with patients' largest tumor ≤ 3 cm, and the other with patients' largest tumor > 3 cm.
- 1.4. Store one set of randomization envelopes in the hospital pharmacy, where the bleomycin is produced. **NOTE:** This allows the unblinded pharmacy personnel to prepare the study medicine according to the randomization code.
- 1.5. Store a second set of sealed randomization envelopes in a secure location with controlled access. Allow access to these envelopes only in case of emergency unblinding.

2. Participants inclusion and pretreatment assessment

- 2.1. Screen patients according to the prespecified inclusion and exclusion criteria¹². **NOTE:** Detailed in- and exclusion criteria are presented in Table S2.
- 2.2. Obtain informed consent.
- 2.3. Confirm eligibility before assigning a randomization number.
- 2.4. Measure all visible cutaneous metastases at baseline.
- 2.5. Stratify patients into two groups according to their largest cutaneous metastasis (≤ 3 cm or > 3 cm).
- 2.6. Assign each patient a pre-generated randomization number corresponding to both the stratification group and treatment allocation (full-dose or half-dose bleomycin).
- 2.7. Register a maximum of seven metastases per patient for response evaluation (baseline registration). **NOTE:** If a patient has more than seven metastases, treat all metastases; however, follow only up to seven metastases for response assessment.

- 2.8. Assign each registered metastasis a unique identification number and measure it in three dimensions using rule-based measurements. Perform photographic documentation.
- 2.8.1. Length: Measure the largest diameter of the metastasis using a ruler aligned with the longest axis. Include the measuring device in the photograph.
- 2.8.2. Width: Measure the widest diameter perpendicular to the longest axis. Document with a photograph including the measuring device.
- 2.8.3. Height: Measure the elevation from the surrounding skin surface to the highest point of the metastasis.
- 2.9. Record all measurements in a study form.

3. Treatment with electrochemotherapy

- 3.1. Preparation of bleomycin must be done in the hospital pharmacy. **CAUTION:** Bleomycin is a cytotoxic chemotherapeutic agent. Handle it using appropriate personal protective equipment (gloves, gown, and eye protection) and prepare it in a certified biological safety cabinet according to institutional cytotoxic drug handling guidelines. Dispose of all contaminated materials as cytotoxic waste¹³.
- 3.1.1. Reconstitute the bleomycin powder with sterile water for injection to obtain a stock solution of 3,000 IU/mL, according to the manufacturer's instructions.
- 3.1.2. Dilute the stock solution with 0.9% sodium chloride to obtain a final infusion volume of 100 mL. **NOTE:** Maintain a total infusion volume of 100 mL for all patients, regardless of whether the full or half dose of bleomycin is prepared.
- 3.1.3. Ensure the infusion bag is labeled only with the patient ID to maintain blinding.
- 3.2. Induction of anesthesia
- 3.2.1. Induce general anesthesia according to institutional standards. **NOTE:** Local anesthesia may be used if clinically indicated.
- 3.2.2. If the treatment area involves the head and neck, use a spiral tube when appropriate.
- 3.2.3. Initiate bleomycin infusion when fraction of inspired oxygen (FiO_2) is below 30% and oxygen saturation is clinically acceptable. **NOTE:** Association between oxygen exposure and bleomycin-induced pulmonary toxicity has been reported; therefore, a low FiO_2 is recommended¹⁴

3.3. Bleomycin infusion

- 3.3.1. Administer bleomycin intravenously over 4-5 min. Record the exact time of the infusion start and completion.
- 3.3.2. Wait 8 min after completion of the infusion before starting the electroporation.

3.4. Electroporation

- 3.4.1. Select needle electrodes (linear or hexagonal) according to tumor size. Use hexagonal electrodes for tumors > 3 cm and linear electrodes for tumors ≤ 3 cm.⁴
- 3.4.2. Connect the needle electrode to the external pulse generator.
- 3.4.3. Apply electric pulses to the tumor using the external pulse generator, please see Figure 2. **NOTE:** The external pulse generator must deliver eight square-wave pulses of 0.1 msec at a field strength of 1 kV/cm and a frequency of 1 kHz.
- 3.4.4. Reposition the electrode as necessary to ensure complete coverage of the tumor and a 1 cm safety margin.
- 3.4.5. Repeat the pulse application for each tumor requiring treatment.
- CAUTION:** Follow all safety guidelines for the external pulse generator for handling and delivering electric pulses.
- 3.4.6. Record treatment time, pulse duration, and delivered current for each treated tumor.

[Place **Figure 2** here]

4. Biological samples collection

4.1. Blood samples

- 4.1.1. Collect venous blood samples six times during the procedure: Before bleomycin infusion, and at 5, 10, 20, 30, and 40 min after bleomycin infusion
- 4.1.2. Use a separate peripheral intravenously catheter for blood sampling.
- 4.1.3. Collect samples in lithium heparin tubes. **NOTE:** this is critical for subsequent analysis of the concentration of bleomycin in the samples¹⁵.
- 4.1.4. Protect the samples from direct light and store at room temperature (20 °C) until centrifugation.
- NOTE:** Bleomycin is light sensitive¹⁵.
- 4.1.5. Record the exact time of each collection.
- 4.1.6. After final collection, centrifuge samples at 2000 x g for 10 min at 20 °C. Transfer plasma to 2 mL tubes and store in a -80 °C freezer until further analysis.

4.2. Tumor biopsies

- 4.2.1. Collect 3 mm punch biopsies from tumor tissue five times during the procedure: Before bleomycin infusion, and at 2, 4, 6, and 8 min after bleomycin infusion, please see Figure 3. **NOTE:** Obtain all biopsies from the same tumor for consistency. The tumor has to be at least 10 mm in diameter.
- 4.2.2. Immediately place samples on ice and protect from light.
- 4.2.3. Record exact collection times.
- 4.2.4. Store biopsies in a -80 °C freezer.

4.3. Normal skin biopsies

- 4.3.1. Collect 3 mm punch biopsies from normal skin located 2-3 cm from the tumor before bleomycin infusion and 8 min after bleomycin infusion.
- 4.3.2. Place all samples on ice and protect from light until referral to freezer.
- 4.3.3. Store biopsies in a -80 °C freezer.

5. [Place **Figure 3** here]

6. Primary Endpoint Assessment

- 6.1. Evaluate tumor response three months after treatment.
- 6.2. Perform tumor-level assessment using ruler-based measurements, and photographic documentation, as done described in section 2.7. **NOTE:** If tumor surface is covered by a crust or scab, include the entire area in the measurements
- 6.3. Assess all tumors registered at baseline (up to seven tumors per patient).
- 6.4. Apply the mRECIST criteria¹⁶.
- 6.4.1. Complete Response (CR): full disappearance of the lesion.
- 6.4.2. Partial Response (PR): reduction of at least 30% in the largest diameter.
- 6.4.3. Progressive Disease (PD): increase of at least 20% in the largest diameter.
- 6.4.4. Stable Disease (SD): changes not meeting the criteria for PR or PD.

7. Qualitative Interviews

- 7.1. At inclusion, ask patients whether they wish to participate in qualitative interviews regarding their experiences with cutaneous metastases and ECT. If included proceed with the following.
- 7.2. Conduct one semi-structured interview prior to treatment. Use a predefined semi structured interview guide. **NOTE:** The interviews may take place by telephone, at the patient's home, or at the treatment center, and will last for approximately one hour.
- 7.3. Conduct the second interview as described above three months after treatment.

Further analysis of the biological samples

Biological samples are prepared and analyzed for bleomycin concentration according to previously established protocols^{12,15,17} using ultra-high-performance liquid chromatography (UHPLC) coupled with quadrupole mass spectrometry¹⁵. As the analytical workflow is not the primary focus of this video article, detailed methodological steps are not described here. The sampling points, analytical workflow, and assessed outcomes are summarized in Figure 4.

[Place **Figure 4** here]

REPRESENTATIVE RESULTS:

As this video presentation describes an ongoing randomized, double-blind clinical trial, no definitive results regarding tumor response according to bleomycin dose are available currently. Instead, this section summarizes preliminary observations from the first 15 enrolled patients: 13 women and 2 men. Among these patients, two were diagnosed with malignant melanoma, three with lung cancer, and ten with breast cancer. Baseline tumor characteristics are presented in Table 1.

An example of tumor measurements and response evaluation according to the mRECIST criteria are presented in Figure 5.

[Place **Table 1** here]

[Place **Figure 5** here]

FIGURE LEGENDS:

Figure 1: Study design of BLESS Trial

Previously published by Tolstrup et al.¹². This figure outlines the design of the BLESS Trial, a randomized controlled study. Around 55 palliative patients, representing roughly 110 tumors, will be enrolled. After stratification by tumor size, patients are randomly allocated to receive either the full bleomycin dose or a half dose. The main outcome measure is tumor response three months after treatment. Sixteen patients will also take part in qualitative interviews conducted before and approximately three months after therapy. On the treatment day, blood and tissue samples are collected for pharmacokinetic analysis.

Figure 2: Intraoperative electrochemotherapy procedure for a scalp tumor.

The image shows a treatment session performed in the operating theater with the patient under general anesthesia. The tumor is located on the scalp. Following sterile preparation and draping of the surgical field, and the intravenously bleomycin administration, the treating physician inserts a sterile hexagonal electrode perpendicularly into the tumor tissue. The electrode is connected to the pulse generator, and electric pulses are delivered according to the predefined treatment parameters described in the protocol. To ensure complete tumor coverage, the electrode is repositioned sequentially until the entire tumor area, including a margin of 10 mm, has been treated.

Figure 3: Operating room setup.

The image shows the operating theater during the procedure. In the foreground, a tumor biopsy is handled prior to electroporation. In the background, the electroporator and its display screen are visible. Simultaneously, the treating physician is preparing to start electroporation.

Figure 4: Timeline and Analytical Workflow for Biological Sample Collection and Bleomycin Quantification

Previously published by Tolstrup et al.¹². The figure presents the timeline for biological sample

collection during the treatment day. Plasma and tissue samples will undergo analysis using Ultra-High-Performance Liquid Chromatography (UHPLC) combined with mass spectrometry. Measured bleomycin concentrations will be correlated with tumor cell fraction, patient age, body surface area, and renal function parameters.

UHPLC: Ultra High Performance Liquid Chromatography

Figure 5: Representative clinical response assessment using mRECIST criteria.

(A) Baseline clinical presentation of a 77-year-old woman with breast cancer and multiple cutaneous metastases located at the anterior thoracic wall and abdomen. The image shows several cutaneous metastases beneath the right breast. Two tumors in this area were registered at baseline for response evaluation according to mRECIST criteria.

Tumor 1 measurements: largest diameter 20 mm; perpendicular diameter 15 mm; thickness 2 mm.

Tumor 2 measurements: largest diameter 20 mm; perpendicular diameter 14 mm; thickness 4 mm.

(B) Clinical appearance at follow-up after treatment. No measurable tumors are detectable in the previously treated areas. Post-treatment skin changes including thickening and hyperpigmentation are visible within the treated field. According to mRECIST criteria, the patient achieved a complete response for the registered tumors.

Table 1: Tumor characteristics for the first 52 tumors included in BLESS Trial

The table presents key tumor characteristics, including primary tumor origin, tumor size, and previous electroporation status. The number and corresponding percentage of tumors within each category are shown.

Table S1: Endpoints of BLESS Trial

Previously published by Tolstrup et al.¹².

Table S2: In- and exclusion criteria of BLESS Trial

Previously published by Tolstrup et al.¹².

DISCUSSION:

A detailed description of the protocol has previously been published¹². This video article provides a visual and practical overview of the double-blinded, randomized clinical trial, including qualitative interviews and a description of the pharmacokinetic analyses. By illustrating the procedural workflow and critical methodological steps, the video complements the written protocol and facilitates reproducibility. The study offers a structured framework for evaluating both the mechanisms and clinical application of ECT¹².

Several steps in the protocol are critical to ensure valid evaluation of ECT administered with two different doses of bleomycin. One key step is standardized tumor measurement at baseline and at the three-months follow-up, when treatment response is assessed. The tumors in this heterogeneous patient population vary considerably in size, morphology, and anatomical location,

which may complicate consistent measurement. Tumors that are purely demarcated require predefined consensus-based assessment strategies. For example, in cases where multiple small tumors become confluent, the study team agreed to measure the confluent area as a single tumor. To ensure consistency and minimize interobserver variability, all ambiguous cases must be discussed within the study team. Furthermore, only a limited number of trained investigators perform tumor measurements, and whenever possible, the same investigator conducts both baseline and follow-up assessments for each individual patient.

Another critical procedural component is electrode placement, including electrode length selection and repositioning during treatment. In this protocol, electrode placement is performed by trained plastic surgeons who have received standardized instructions in both study protocol and electroporation techniques prior to participation. Although this approach promotes procedural consistency, some degree of individual clinical judgement remains unavoidable, particularly regarding needle depth and positioning. Reproducibility could potentially be further strengthened by limiting the number of treating surgeons to one or two dedicated operators.

Protocol deviations most commonly occur during intra-procedural blood sampling for pharmacokinetic analyses. Many of the included patients are heavily pretreated and may have compromised venous access due to prior systemic therapy and comorbidities. Consequently, complete blood sampling at all predefined time points is not always feasible. These deviations are documented and considered in the pharmacokinetic analyses.

Compared to existing ECT protocols⁴, which use standard bleomycin dose, this protocol provides a structured and holistic approach to evaluating ECT with reduced-dose bleomycin. Beyond measuring tumor response, it incorporates patient-centered outcomes and pharmacokinetic insights, thereby strengthening the evidence base for optimizing ECT in clinical oncology. If non-inferior tumor control can be demonstrated, dose reduction may expand the therapeutic window, particularly for elderly or multimorbid patients, by reducing the risk of toxicity without compromising treatment efficacy.

ACKNOWLEDGMENTS:

This work was supported by The Danish Cancer Society (grant number R325-A18717). The study also received funding from Region Zealand Health Science Research Foundation (grant number R46-A2242), the NEYE foundation, the Agnethe Løvgreen Foundation and the Dagmar Marshall Foundation.

DISCLOSURES:

None of the authors declare any conflict of interest.

REFERENCES:

- 1 Tormena, C. C., Cury-Martins, J., Miyashiro, D. & Sanches, J. A. in *Cutaneous Metastases* eds Cristina Martinez Zugaib Abdalla, José Antonio Sanches, Rodrigo Ramella Munhoz, & Francisco Aparecido Belfort) 539-556 (Springer International Publishing, 2023).
- 2 Tsihlikidou, A. *et al.* Intervention for symptom management in patients with malignant fungating wounds - a systematic review. *J BUON*. **24** (3), 1301-1308 (2019).
- 3 Vestergaard, K., Vissing, M., Gehl, J. & Lindhardt, C. L. Qualitative Investigation of Experience and Quality of Life in Patients Treated with Calcium Electroporation for Cutaneous Metastases. *Cancers*. **15** (3), doi:10.3390/cancers15030599, (2023).
- 4 Gehl, J. *et al.* Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases. *Acta Oncologica*. **57** (7), 874-882, doi:10.1080/0284186X.2018.1454602, (2018).
- 5 NICE. *Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma*, <<https://www.nice.org.uk/guidance/ipg446>> (2013).
- 6 Amaral, T. *et al.* Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol*. **36** (1), 10-30, doi:10.1016/j.annonc.2024.11.006, (2025).
- 7 Clover, A. J. P. *et al.* Electrochemotherapy in the treatment of cutaneous malignancy: Outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008–2019). *European Journal of Cancer*. **138** 30-40, doi:10.1016/j.ejca.2020.06.020, (2020).
- 8 Rotunno, R. *et al.* Electrochemotherapy of unresectable cutaneous tumours with reduced dosages of intravenous bleomycin: analysis of 57 patients from the International Network for Sharing Practices of Electrochemotherapy registry. *Journal of the European Academy of Dermatology and Venereology*. **32** (7), 1147-1154, doi:10.1111/jdv.14708, (2018).
- 9 Sersa, G. *et al.* Outcomes of older adults aged 90 and over with cutaneous malignancies after electrochemotherapy with bleomycin: A matched cohort analysis from the InspECT registry. *European Journal of Surgical Oncology*. **47** (4), 902-912, doi:10.1016/j.ejso.2020.10.037, (2021).
- 10 Jamsek, C., Sersa, G., Bosnjak, M. & Groselj, A. Long term response of electrochemotherapy with reduced dose of bleomycin in elderly patients with head and neck non-melanoma skin cancer. *Radiology and Oncology*. **54** (1), 79-85, doi:10.2478/raon-2020-0009, (2020).
- 11 Bastrup, F. A., Vissing, M. & Gehl, J. Electrochemotherapy with intravenous bleomycin for patients with cutaneous malignancies, across tumour histology: a systematic review. *Acta Oncologica*. **61** (9), 1093-1104, doi:10.1080/0284186X.2022.2110385, (2022).
- 12 Tolstrup, M. A. *et al.* Study Protocol for a Randomized Clinical Trial Investigating the Effect of Reduced Bleomycin in Electrochemotherapy Treatment on Patients with Cutaneous Metastases (The BLESS Trial). *Bioelectricity*. **7** (4), 242-251, doi:10.1177/25763113251377404, (2025).
- 13 Neon Healthcare Ltd. *Summary of Product Characteristics: Bleomycin 15000 IU Powder*

for solution for injection/infusion.,
<https://www.medicines.org.uk/emc/product/15505/smpc?utm_source=chatgpt.com>
(

- 14 Azambuja, E., Fleck, J. F., Batista, R. G. & Menna Barreto, S. S. Bleomycin lung toxicity: who are the patients with increased risk? *Pulm Pharmacol Ther.* **18** (5), 363-366, doi:10.1016/j.pupt.2005.01.007, (2005).
- 15 Plesnik, H., Bosnjak, M., Cemazar, M., Sersa, G. & Kosjek, T. An effective validation of analytical method for determination of a polar complexing agent: the illustrative case of cytotoxic bleomycin. *Analytical and Bioanalytical Chemistry.* **415** (14), 2737-2748, doi:10.1007/s00216-023-04675-x, (2023).
- 16 Eisenhauer, E. A. *et al.* New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *European Journal of Cancer.* **45** (2), 228-247, doi:10.1016/j.ejca.2008.10.026, (2009).
- 17 Kosjek, T. *et al.* Identification and quantification of bleomycin in serum and tumor tissue by liquid chromatography coupled to high resolution mass spectrometry. *Talanta.* **160** 164-171, doi:10.1016/j.talanta.2016.06.062, (2016).